Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records. J of Skin 2019, 3 (2), 173. https://doi.org/10.25251/skin.3.2.13.